The treatment of children with acute leukemia has been improved dramati cally during the last decade and now curative approach can be expected. Although there has been a perceptible improvement in the treatment of adult acute non-lymphoblastic leukemia, it is not yet comparable with the success in childhood leukemia. Recently, many reports using combination chemotherapy indicate the complete remission rate of 50% or more and the median survival less than a year. It is our purpose in this article to show the remarkable advance in the treatment of adult non-lymphoblastic leukemia using an intermittent combina tion chemotherapy with daunomycin, cytosine arabinoside, 6 mercaptopurine, and prednisolone (DCMP protocol). By DCMP protocol, in particular, by the two step method complete remission in more than 80% of adult patients with acute non lymphoblastic leukemia and remarkable prolongation of leukemia free survival has been obtained since 1971 in our clinic.
METERIALS AND METHODS

Patients.
Thirty-two patients with acute non-lymphoblastic leukemia (ANLL) includ ing 13 patients with acute myeloblastic leukemia (AML), 17 patients with acute monocytic leukemia (MOL), one patient with acute promyelocytic leukemia (APL) and one patient with erythroleukemia (EL) were subjected for this study. Their ages were ranging between 15 and 74. Other forms of acute leukemia such as blastic crisis of chronic granulocytic leukemia and cases of preleukemia were omitted from this study.
The diagnosis of acute leukemia and classification of leukemic cell types were made by examining both peripheral blood and bone marrow smears using May-Giemsa staining and histochemical procedure including peroxidase, non-specific esterase, acid phosphatase, alkaline phosphatase and PAS staining.
In most patients electron-microscopic findings of leukemic cells and phagocytic function of leukemic cells were also investigated. Induction therapy. The first induction course consisted of a 5 to 14 day-course of 6 mercaptopurine (1 to 4 mg per kg daily) and cytosine arabinoside (0.4 to 2.0 mg per kg daily), perdnisolone (20 to 60 mg daily) which was tapered off and daunomycin (0.4 to 0.8 mg per kg) on the first day and the last day of the course. The second course of treatment was given within one week after completion of the initial course. The dosage of the drugs and duration of the treatment were less than those in the initial course. With the first step treatment in this schedule leukocyte counts decreased below 1500/mm3 and bone marrow nucleated cell counts decreased down to less than 15000 to 20000/mm3 by adjusting the dose and the, numbers of the days of the drug administration, so that the decrease of leukemic cells in the bone marrow and increase of the lymphocytic ratio were obtained. If these were achieved, then, after 3 to 7 days of a resting period, the patients were again treated by the second step of treatment with relatively lower dose of medica tions (Fig. 2) . By this two step method complete remission could be achieved after the completion of the second step therapy in almost all patients. In the therapy, the same kinds of agent were used.
However, the period of drug administration was for 5 days and the rest period was for 2 to 3 weeks.
Maintenance
therapy.
The maintenance therapy was given in the same way as the consolidation therapy with intervals of 8 to 12 weeks. Besides, methotrexate 20 mg per week and cytosine arabinoside 40 to 80 mg once a week were given in the period of 6 to 12 months.
The time of the termination of the treatment was settled at 3 years after the induction of the complete remission was achieved. 3H Thymidine labeling procedures. Bone marrow samples were labeled with 3H TdR in vitro and smears of cells labeled with 3H TdR were dipped in Fuji emulsion film and were exposed for 5 days, then developed, fixed and stained with May-Giemsa staining.
Evaluation and criteria for remission. Full blood counts were done daily and bone marrow examinations were repeated every 3 to 7 days during remission induction. Renal and liver function were assessed once a week. Blood counts and bone marrow examination were also repeated during consolidation and maintenance therapy but less frequently.
Complete remission was judged from Kimura's criteria (Sakana and Kimura 1974) and the criteria established by the Midwest Cooperative Study Group.
RESITLTS
Remission induction. The number of patients who achieved a complete remission is shown in Table 1 . Twenty-six of 32 patients with ANLL had complete remission (81%). The complete remission was achieved in 11 of 13 patients with AML (85%), in 13 of 17 patients with MOL (77%), and in each one patient with APL and erythroleukemia.
Factors influencing remission rate. Early deaths due to hemorrhage and infection in the patients who received inadequate trials of chemotherapy somewhat influenced remission rate but not so seriously, because in the present schedule of treatment the patients became well soon after initiation of the treatment in responders and the critical period is within 7 to 10 days after initiation of the therapy. The complete remission rate in the patients under the age of 50 was 81% and in the patients aged 50 years or more it was about the same, i.e. 83%. There was significant difference in complete remission rate between males (64%) and females (94%). The rate in patients with an initial WBC count less than 20000/mm3 was higher than that in patients with more than 20000/mm3, but the difference was not statistically significant. There was no significant difference be tween patients with a platelet count of less than 20000/mm3 and more than 20000/ mm3 ( Table 2 ).
Number of courses of therapy and term required to induce complete remission are shown in Table 3 . Four of 26 responders went into complete remission after the first course of induction therapy , 20 responders after 2 courses and 2 responders after 3 courses.
In patients who could not go into complete remission till the third course, no complete remission was obtained after further courses of therapy .
The median time from the initiation of therapy to complete remission was 35 days in all responders and 37 days in the patients with complete remission of more than Hematological changes during remission induction. The maximal bone marrow depression was achieved after the remission induction therapy especially after the second step treatment (Fig. 3) . Acellular bone marrow was observed in 20 cases. Of these, 19 patients achieved complete remissions and one died without recovery of hematopoietic activity.
Hypocellular bone marrow was observed in 9 cases. Of these, 7 patients achieved complete remission and 2 patients remained at the partial remission stage. All patients who remained blastic after treatment showed no remission.
The changes observed in the bone marrow findings during remission induction therapy by the two-step method were shown in Fig. 4 . Nucleated cell counts in the bone marrow showed a marked decrease after the first step of treatment.
In contrast, in patients with non-complete remission, the decrease was less marked and there was a tendency to increase after a short period of resting. Changes of in vitro 3H-Thymidine labeling of the bone marrow leukemic cells. As shown in Fig. 5 , the labeling index and mean grain count (MGC) of bone marrow leukemic cells decreased by the end of the first step treatment, then both showed rapid increase after the termination of the treatment and labeling index rose higher than pre-treatment level within 5 to 10 days of rest period. However, mean grain count showed still lower level at the rest period in the majority of the Toxicity. Nausea and vomiting occurred during nearly all courses of therapy, being mild to moderate in most cases. Headache occurred in 15% of the patients. Malaise and alopecia was observed in 8% of the patients. Cardiotox icity was observed in 4% of the patients. Injury of liver function was observed in 23% of the patients during the therapy but there was no evidence of liver toxicity that could be attributed to chemotherapy and no further treatment resulted in serious injury of liver function. The complete remission rate was 81% of 32 patients. Our results are excellent compared with the results obtained by other study groups. Clarkson (1972) reported complete remission rate of 65% in a series of 43 patients treated with thioguanine and cytosine arabinoside. Crowther et al. (1973) obtained complete remission in 39 of 72 patients with acute myelogenous leukemia using combination chemotherapy of cytosine arabinoside and daunorubicin. Rosenthal and Moloney (1972) also reported the complete remission rate of about 50% in 23 patients with acute myelogenous leukemia using a combination of vincristine, cytosine arabinoside and daunorubicin (COAP). McCredie et al. (1972) obtained complete remission in 60% of the patients with acute myelogenous leukemia using a combination of prednisone, vincristin, methotrexate and 6 -mercaptopurine (POMP). Hirano et al. (1972) reported a combination therapy with daunorubicin, cytosine arabinoside, 6-mercaptopurine and prednisolone (DCMP) and in this protocol complete remission was obtained in 64% of 34 patients with acute non-lymphoblastic leukemia. Consequently, the complete remission rate in our hospital is the best one so far published in the adult patients with acute non-lymphoblastic leukemia, and the remission rate has reached the level in childhood leukemia. As for DCMP combination therapy, Kamei et al. (1970) first devised the combination of these drugs but the programs of intermittent combination therapy of DCMP were developed by Hirano et al. (1972) and our unit independently. Spiers (1972) presented TRAP therapy using thioguanine instead of 6 mercaptopurine in DCMP program.
DISCUSSION
It is now established that in the treatment of the acute leukemia it is essential to reduce the leukemic cell population to nearly zero as possible. In ANLL unlike ALL it is virtually impossible to obtain a complete remission unless the patients go through a period of profound marrow hypoplasia.
In the present intermittent combination therapy of ANLL, 4 to 5 day-courses are repeated at 2 to 3 week intervals until a remission is obtained.
It is considered that a rest period usually for about 2 to 3 weeks is then allowed to permit regeneration of the normal cells after which therapy is resumed.
However, by our studies based on the investigation of the cell kinetics it was proved that within 5 to 7 days of rest period leukemic cells which escaped being killed by the first course treatment already began to remultiply and recruitment of surviving quiescent cells to proliferating pool began while proliferation of normal bone marrow cells, particularly erythropoiesis, being suppressed probably due to inhibitory interaction of leukemic cells before treatment, was so profoundly suppressed during the first course of the treatment that regeneration of erythroblasts was delayed, and did not occur till leukemic cells disappeared after the second course of the treatment. notable that our two-step treatment is the minimal amount of cytotoxicity on the normal hematopoietic cells as well as other normal tissues so that patients can survive long enough to receive an adequate trial. This is the reason why in our study the incidence of remission in the older patients as well as in the younger patients has been high compared with results from other reports. We have established DCMP two-step treatment method based on the cell kinetics of bone marrow leukemic cells and normal bone marrow cells. The method is definitely effective for the treatment of acute leukemia in adults. The complete remission rate is the highest, and the median duration of complete remission and survival for patients receiving this regime is also the longest among reports thus far appeared which dealt with patients comprised of adults with ANLL. Now more than 20% of the patients showed long remission duration of more than 2 years, and if they continue as they are, the achievement of 5-year-cure can surely be expected.
